Category: Uncategorized
Changes to the Roche Board of Directors and the Corporate Executive Committee
Basel, 1 February 2022 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the United States, effective 18 March 2022. Johannes (Hans) Clevers (1957), M.D., Ph.D.,... Read more
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
FRANKLIN LAKES, N.J., Feb. 1, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring... Read more
Xylem Earns Top Score for Workplace Equality from Human Rights Campaign for Third Year Running
RYE BROOK, N.Y.–(BUSINESS WIRE)–Jan. 27, 2022– Xylem (NYSE:XYL), a leading global water technology company, has today announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index. This is the third year in a row that Xylem has earned top marks on the U.S. benchmarking survey which measures... Read more
The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME) Across four studies, about half of eligible faricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longer... Read more
Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization
Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization | IR News | News Release ＆ IR News | Investor Relations Read more
Xylem Clocks 113,000 Volunteer Hours in 2021, Doubling Time Donated to Help Tackle Water Challenges in 55 Countries
RYE BROOK, N.Y.–(BUSINESS WIRE)–Jan. 20, 2022– Global water technology company, Xylem (NYSE:XYL), announced today that almost 80 percent of its 16,000 employees volunteered their time to help solve urgent water challenges in 2021. Xylem’s global team collectively donated 113,000 hours in their communities, across 55 countries. The commitment of volunteer hours doubled from 2020 to... Read more